Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

Also called NCT02194595

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02194595
Other papers using this trial's data
  • The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes Cardiovascular diabetology, 2023-03-09 DOI, PubMed 36894921, PMC9998007 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02194595. Randomized; no masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2021-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
Acronym
PREVAIL
Intervention (Drug)
Basal insulin and exenatide
Intervention (Drug)
Basal insulin only
Intervention (Drug)
Basal insulin and bolus insulin
Lead sponsor
Mount Sinai Hospital, Canada (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)
Collaborator
University of Toronto (class: other)

Record details

Record id
cardio:ct-nct02194595
Content hash
3c3aff4ba7e6b046df08104f46dbe6cbd99200a590977d180db75a5c933c8267